Greenwich LifeSciences, Inc. (GLSI) shares are down on Monday morning trade, after reaching an all-time peak last week.
The company shares have spiked as the biopharma company announced zero percent recurrence of breast cancer in its GP2 Phase IIb clinical trial through a poster presentation. On December 09, the shares have reached a high of 158.07.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com